Mizuho Maintains Buy on Corteva, Raises Price Target to $78
Mizuho analyst Christopher Parkinson maintains Corteva (NYSE:CTVA) with a Buy and raises the price target from $76 to $78.
Morgan Stanley Maintains Overweight on Corteva, Raises Price Target to $80
Morgan Stanley analyst Vincent Andrews maintains Corteva (NYSE:CTVA) with a Overweight and raises the price target from $70 to $80.
UBS Downgrades Corteva to Neutral, Raises Price Target to $73
UBS analyst Joshua Spector downgrades Corteva (NYSE:CTVA) from Buy to Neutral and raises the price target from $70 to $73.
Loop Capital Downgrades Corteva to Hold, Raises Price Target to $71
Loop Capital analyst Christopher Kapsch downgrades Corteva (NYSE:CTVA) from Buy to Hold and raises the price target from $70 to $71.
RBC Capital Maintains Outperform on Corteva, Raises Price Target to $78
RBC Capital analyst Arun Viswanathan maintains Corteva (NYSE:CTVA) with a Outperform and raises the price target from $72 to $78.
Credit Suisse Maintains Outperform on Corteva, Raises Price Target to $74
Credit Suisse analyst John Roberts maintains Corteva (NYSE:CTVA) with a Outperform and raises the price target from $72 to $74.
Earnings Scheduled For November 3, 2022
Companies Reporting Before The Bell
• Hyatt Hotels (NYSE:H) is estimated to report quarterly earnings at $0.28 per share on revenue of $1.45 billion.
10 Analysts Have This to Say About Corteva
Within the last quarter, Corteva (NYSE:CTVA) has observed the following analyst ratings:
Mizuho Maintains Buy on Corteva, Raises Price Target to $74
Mizuho analyst Christopher Parkinson maintains Corteva (NYSE:CTVA) with a Buy and raises the price target from $69 to $74.
Corteva Agriscience Signs Agreement To Acquire Biological Leader Symborg Subject To Customary Closing Conditions; No Terms Disclosed
Executing on Strategy for Accelerating Vision to Become Biologicals Leader; Delivering Natural Options that Help Farmers Meet Changing Market Expectations
INDIANAPOLIS and MURCIA, Spain, Sep. 22,